Sabal therapeutics, LLC announced that they have entered into an exclusive sales and marketing agreement with Athena Bioscience, LLC to promote Athena's cardiovascular product portfolio. The commercial launch for two products, Nexiclon™ XR and Fibricor®, will occur in April 2022.
Nexiclon XR (clonidine) is the first and only once-daily extended-release tablet indicated for the treatment of hypertension.1 Nexiclon XR provides the antihypertensive clinical benefits of immediate-release clonidine in a convenient, once-daily tablet.2 Fibricor (fenofibric acid) is indicated as adjunctive therapy to diet for the treatment of high triglycerides and high cholesterol. Fibricor significantly improves all cholesterol parameters, including triglycerides, total cholesterol, LDL-C ("bad" cholesterol), and HDL-C ("good"' cholesterol).3
"This partnership aligns perfectly with Sabal's mission to support companies by helping them deliver their products to physicians and patients who need them," said Wade Harper," Sabal's Chief Commercial Officer. "We are very excited to partner with Athena to provide much needed relief for patients struggling with hypertension and high cholesterol."